POC for PCSK9

Regeneron, Sanofi have first proof of concept for PCSK9 mAb to lower cholesterol

Regeneron Pharmaceuticals Inc. and partner Sanofi have become the first companies to report Phase II proof-of-concept data that validate blocking PCSK9 as a strategy for lowering LDL-C in patients not controlled on standard statin therapy. The companies hope to cement their first-mover status by moving into Phase III by mid-2012.

Despite the success of statins, the need for new ways to lower LDL-C has never been greater, according to Regeneron EVP and CSO George Yancopoulos. "Statins lower cholesterol by 40-50% when taken by intensive dosing regimens, but there are still millions of people not reaching their cholesterol goal who are thus left at high cardiovascular risk," he said.

Proprotein convertase subtilisin/kexin type

Read the full 1100 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE